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Materials and methods
Patients and lesions
sensitive imaging method to de reast cancer.1e3 Pre-
vious studies have shown its advantages in lesion detection A prospective study focusing on breast lesion character-mammography and/or ultrasound, preoperative staging,and characterization when compared to mammography
and ultrasound.4e6 Moreover, guidelines and recommen-
dations based on previous single and multicentre studies7,8
were established for its use in the clinical practice.3,9e11
Breast MRI protocols include dynamic contrast-
enhanced (DCE) images with high spatial and temporal
resolution.12 Interpretation of those images integrates
morphological and kinetic descriptors from the breast im-
aging report and data system (BIRADS)-MRI lexicon,
allowing lesion classification and appropriate recommen-
dations for patient management.13
The relevant information regarding DCE lesion kinetics
was previously studied.14e18 The kinetic descriptors rely
on tracking the signal intensity (SI) over time, during two
phases following a bolus injection of contrast medium: the
early phase (wash in) and the delayed phase (washout).
Both provide physiological information on lesion vascu-
larity. Kuhl et al.19 reported that the kinetic predictors
most associated with malignancy were rapid early
enhancement followed by a washout curve in the delayed
phase.
A recent meta-analysis by Peters et al.20 including 44
studies, assessed the diagnostic performance of DCE in
breast cancer, with an overall sensitivity and specificity of
90% and 72%, respectively. Themoderate specificity reflects
some overlap in the morphological and kinetic features
between benign and malignant lesions, which lead to
false-positive cases. The direct consequence of a false-
positive diagnosis is that it could result in unnecessary
biopsy.
To increase breast MRI specificity, other sources of im-
age contrast should be explored. Diffusion-weighted im-
aging (DWI) is a promising method. The apparent diffusion
coefficient (ADC) quantifies the restriction to the random
motion of water molecules within tissues, probing their
properties at the cellular level.21 The ADC is estimated
from the SI decay between two or more diffusion-
weighting factors (b-values).22 Increased cellularity re-
stricts the diffusivity of water molecules within tissues,
leading to low ADC values.23 Previous studies have
demonstrated the role of DWI in breast lesion detection
and characterization.24e26
Considering that DWI and DCE kinetics reveal distinct
physiological and functional characteristics of the lesion
environment, it is likely that combining both may improve
lesion characterization. Studies exploring DWI and DCE
ogether have recently been performed,27e30 suggesting
hat the specificity and accuracy can be increased. Based on
hose results, it is important to evaluate the ability of the
wo combined parameters to predict lesion malignancy.
herefore, the purpose of the present study was to exploretic parameters, and
lignancy.ization using DWI-MRI at 3 T was conducted between 2009
and 2012. The studywas approved by the Institutional Ethics
Committee (protocol: CES 276/13). Women with clinical in-
dications for breastMRIgave theirwritten informedconsent.
During 2011, breast MRI examinations were performed
in 82 consecutive patients. Clinical indications included
unknown primary malignancy, suspicious lesions onbreast cancer screening in women at high-risk, therapeutic
monitoring, follow-up after surgery, breast cancer recur-
rence, and evaluation of implant integrity.
For all pre-menopausal women, breast MRI was per-
formed between the 7th and 14th day of the menstrual cycle
to reduce hormonal variations and minimize the enhance-
ment on the fibroglandular tissue.31,32
For the purpose of this study, exclusion criteria were
applied to patients (1) who had lesions that were biopsied
before the MRI examination (n¼7); (2) subjected to breast
surgery within <6 months (n¼6); (3) undergoing radio-
therapy and/or chemotherapy within the previous 48
months (n¼5); (4) with only simple cystic lesions (n¼6); (5)
who had completed hormone-replacement therapy within
<24 months (n¼3); (6) with breast implants (n¼1); and (7)
whose images had motion artefacts (n¼3).
Lesions were included in the analysis if: (1) they were
solid; (2) the histological results or a minimum of 2-year
follow-up with mammography, ultrasound, or breast MRI
were available33; (3) their size was 7 mm; and (4) they
were classified as 3 to 5 in the BIRADS-MRI lexicon and
were not biopsy-proven prior to breast MRI examination to
exclude the influence of haematoma and/or oedema in the
ADC estimates.
Acquisition protocol
All the examinations were performed using a 3 T MRI
system (Magnetom Tim Trio, Siemens Medical Solutions,
Erlangen, Germany) using a four-channel phased-array coil
 Table 1
Scanning magnetic resonance imaging (MRI) protocol.
Parameters Conventional pre-contrast DWI-SPAIR Dynamic Post-contrast
Sequence T2W TSE T1W 3D FLASH STIR Single-shot EPI T1W 3D FLASH T1W 3D FLASH
Orientation Axial Bilateral Sagittal Unilateral Sagittal Unilateral Sagittal Unilateral Axial Bilateral Sagittal Unilateral
TR/TE (ms) 4990/88 17/4.9 4920/67 4900/106 3.77/1.42 7.8/3.9
TI (ms) e e 210 e e e
Fat suppression e e STIR SPAIR SPAIR Water excitation
FOV (mm2) 320320 200200 200200 250250 320320 160160
Matrix 512384 275384 448314 84128 358448 256256
Section thickness (mm) 4 2 4 5 0.9 0.9
Number of sections 26 64 26 16 160 144
NEX 2 1 2 3 1 1
Bandwidth (Hz/pixel) 305 430 248 1628 490 450
Scan time (min) 2:06 3:49 4:26 5:58 4:32 3:12
b-values (s/mm2) e e e 50,200,400, 600,800,1000,
2000 and 3000
e e
DWI-SPAIR, diffusion-weighted imaging with spectrally adiabatic inversion recovery; TSE, turbo spin eco; T1W 3D Flash, T1-weighted three-dimensional
gradient echo fast low angle shot; EPI, echo planar imaging; TR/TE, repetition time/echo time; TI, inversion time; STIR, short tau inversion recovery; FOV,
field of view; NEX, number of excitations.(Invivo, Corporation, United States) with the patients lying
in the prone position. The protocol included conventional
MRI and DWI sequences. The sequential order of the ac-
quisitions is presented in Table 1.
Axial dynamic images were acquired, one before and five
phases after bolus injection of gadobenate dimeglumine
(MultiHance; Bracco, Milan, Italy). Automatic injection was
performed via the antecubital vein at a rate of 2 ml/s (total
dose 0.1 mmol/kg body weight), followed by a 20 ml saline
flush.
The DWI acquisitionwas performed before DCE. A single-
shot spin-echo echo planar imaging (SS-SE-EPI) sequence
with eight b-values was used. The diffusion gradients were
applied along the x-, y-, and z-directions to generate three-
scan-trace images.
To avoid having to estimate the SI for all DWI images and
simplify the analysis, only the images with b-values of 50
and 1000 s/mm2 were used to estimate the ADC. These b-
values were chosen according to a previous study aiming to
determine the best pair of b-values for breast lesion dif-
ferentiation.34 The higher b-values were used to investigate
non-Gaussian diffusion of water in lesions.35
Including higher b-values (2000 and 3000 s/mm2) in the
protocol resulted in prolonging the echo time (TE) from 78
to 106 ms. As the T2 relaxation time for normal glandular
tissue is 716 ms,36 the predicted signal loss from using a
longer TE is of 33%. To compensate for this, the number of
excitations was increased to 3.
Fig 1 illustrates a case of a 57-year-old woman with a
suspicious breast mass located in the upper half of the right
breast.
Image analysis
All the datasets were evaluated on the scanner work-
station (Syngo Multimodality, Siemens Healthcare, Erlan-
gen, Germany) with the commercial software (Syngo MR
version 17A). The same experienced radiologist (with 6
years of experience in breast MRI) evaluated all the exam-
inations prospectively. Lesion interpretation was based onthe BIRADS-MRI lexicon according to morphological and
kinetic criteria.13 For each lesion, the location and size were
reported. Lesion size was determined from DCE images and
the largest dimension was considered. The morphological
features of mass lesions were described (type, shape,
margin, and internal enhancement), while for non-mass
lesions, the distribution, internal enhancing pattern, and
symmetry of enhancement were noted.
The analysis of kinetic parameters was performed on the
early T1-weighted subtracted images. For each lesion re-
gions of interest (ROIs) were placed within the area
showing the strongest enhancement, and timeeSI curves
were created. The early phase wasmeasured in the first 1e2
minutes (wash-in rate) after gadolinium injection, and was
described as either slow, medium, or rapid. A wash in rate
greater than 80% was classified as fast; between 50% and
80% as medium (intermediate); and less than 50% as slow.12
After peak enhancement, the delayed phase (washout)
corresponding to the remaining time course of the SI curve
was classified as having persistent (type I), plateau (type II),
and washout (type III) curves. A persistent pattern implies
that the SI keeps on increasing during the measurement
time; the plateau is typically a curve with constant SI after
the early phase. The washout pattern describes the cases for
which the SI decreases more than 10% over time, after
reaching its highest point in the early phase. Information
regarding conventional MRI was based on the clinical MRI
report and histopathology results.
The DWI images were analysed by locating the lesions on
the conventional MRI images using the information on the
clinical report. To measure lesion SI, fixed ROIs of 0.25 cm2
were drawn firstly at b¼1000 s/mm2, in the section with
largest lesion dimension and best definition of its borders,
within the area with highest hyperintensity. During ROI
demarcation, care was taken to exclude normal fibro-
glandular tissue, necrotic or cystic areas, and regions with
high T2 signal within the lesion. The ROIs were then copied
to the b¼50 s/mm2 images. For each lesion, the mean value
and standard deviation (SD) of the SI were recorded.
Figure 1 A 57-year-old woman with a suspected malignant lesion in the right breast. (a) Axial short-tau inversion recovery (STIR) shows a large
hyperintense lesion with slight hypointense borders. (b) DWI at b¼1000 s/mm2 and (c) the corresponding ADC map. (d) DCE image shows a
mass with irregular borders and (e) demonstrating rapid initial contrast enhancement in the early phase followed by washout curve. The
histological result revealed an invasive ductal carcinoma grade III, which was in agreement with the ADC value of 0.63103 mm2/s.
Table 2
Characteristics of 69 breast lesions and comparison between lesion types.
DCE findings Malignant (28) Benign (41) p-Value
No. % No. %
Size 0.10
7e10 mm 8 28.6 11 26.9
11e20 mm 10 35.7 23 56.0
21 mm 10 35.7 7 17.1
Lesion type 0.31a
Mass 22 78.6 36 87.8
Non-mass 6 21.4 5 12.2
BI-RADS <0.001a
3 3 10.7 19 46.3
4 10 35.7 13 31.7
5 15 53.6 5 12.2
Diagnostic source <0.001
Biopsy 28 100.0 30 73.2
Follow-up 0 0 11 26.8
a Fisher exact test.The ADC estimate was determined using a linear fitting
to the mono-exponential model and two b-values (50 and
1000 s/mm2) using the equation21:
ADC ¼ ln½Sðb1Þ  ln½Sðb2Þ
b2  b1
where S(b) represents the signal intensity, and b1 and b2 are
the two b-values.
Statistical analysis
To characterise the study population, descriptive analysis
was performed. The prevalence of lesions characteristics
(benign or malignant) was compared using the Pearson chi-
squared test (c2) and the Fisher’s exact test. A one-way
ANOVA (analysis of variance) was used to evaluate the as-
sociation between ADC and kinetic parameters (early-phase
and delayed-phase curve). Mean ADC values and kinetic
parameters were compared for benign and malignant le-
sions using the independent sample t-test and the Chi-
squared test. Models for binary outcome, considering ADC
and kinetic parameters as predictors of malignancy, were
studied by multilevel regression using the generalized
estimating equations (GEE), to account for multiple lesions
in the same patient.
The goodness of fit of the models (accuracy) was esti-
mated by the corrected maximum quasi-likelihood underthe independence confidence model criterion (QICC): a
lower QICC corresponds to a better fit.
Considering curve type and ADC values (quartiles) as
predictor variables, the predictive ability for malignancy of
the models was calculated. ADC was classified as either
lower than the 25% quartile, higher than the 75% quartile, or
belonging to the intermediate range.
Table 3
Association between apparent diffusion coefficient (ADC) and dynamic
contrast-enhanced magnetic resonance imaging (DCE-MRI) kinetic param-
eters for all lesions (one-way analysis of variance test).All analyses were performed with the PASW version 21.0
and a p-value of less than 0.05 was considered to indicate a
statistical significant value.No. (%) ADC (103 mm2/s)
(Mean  SD)
Association with
ADC (p-value)
Early phase
Slow 2 (2.9) 1.86  0.15 <0.001a
Medium 42 (60.9) 1.72  0.46
Rapid 25 (36.2) 1.24  0.53
Curve type
Persistent 21 (30.4) 1.79  0.49 0.004b
Plateau 35 (50.7) 1.55  0.50
Washout 13 (18.8) 1.17  0.52
a Analysis performed only between medium and rapid uptake of gado-
linium contrast.
b Analysis performed between plateau and washout curve type.Results
The final sample included 51 patients (mean age  SD,
48.42.5 years; age range 21e78 years) with 69 lesions
detected on both DCE-MRI and DWI. Table 2 presents the
characteristics of the lesions and p-values for the compar-
ison between benign and malignant lesions (disregarding
sub-groups).
Thirty-seven patients were premenopausal. Among the
69 lesions found, 28 were malignant lesions. Lesion sizes
ranged from 7 to 74 mm; there were no significant differ-
ences in size between the benign and malignant lesions
(p¼0.10). Eighty-four percent were mass lesions. Consid-
ering the BIRADS classification, 89.3% of the malignant le-
sions were classified as BIRADS 4 and 5, whereas 56.1% of
the benign lesions were classified as BIRADS 3.
Fifty-eight lesions underwent biopsy, from which 28
were classified as malignant. Histopathological results from
the malignant lesions included: six ductal carcinoma in situ
(DCIS), 13 invasive ductal carcinoma (IDC), four lobular
carcinoma in situ (LCIS), three invasive lobular carcinomaFigure 2 A 34-year-old woman with a suspected mass lesion with 13 m
images at b¼1000 s/mm2 revealed a mass lesionwith uniform SI and (b) th
with regular borders with (d) slow initial contrast enhancement in the ear
FA with ADC value of 1.65103 mm2/s.(ILC), and two other malignant lesions (NOS). For the 30
benign lesions, histopathological results revealed 14
fibroadenomas (FA), three papillomas, one hamartoma
(HA), and 12 classified as other benign lesions, namely 11
cases of fibrocystic change (FC) and one complex sclerosing
adenosis (CSA). For the remaining 11 lesions classified as
benign, the diagnosis was established by a 2-year follow-up,
as recommend by Kopans,33 which requires imagingm located in the outer quadrant of the right breast. (a) Sagittal DWI
e corresponding ADC map. (c) Axial bilateral DCE image shows a mass
ly phase, followed by a persistent curve. Histological result indicated a
Figure 3 Boxplot of ADC values by curve type. Comparison of ADC
values between curve types: persistent/plateau*, plateau/washout**,
and washout/persistent***.
Table 4
Univariate comparison between benign and malignant lesions.
Malignant (28) Benign (41) p-Value
Mean  SD Mean  SD
ADC (103 mm2/s) 1.11  0.49 1.74  0.38 <0.001a
Early phase
Slow 0 (0.0%) 2 (4.9%) <0.001b
Medium 9 (32.1%) 33 (80.5%)
Rapid 19 (67.9%) 6 (14.6%)
Curve type
Persistent 0 (0.0%) 21 (51.2%) <0.001b
Plateau 17 (60.7%) 18 (43.9%)
Washout 11 (39.3%) 2 (4.9%)
ADC, apparent diffusion coefficient.
a Student’s t-test.
b Chi-squared test (c2).stability on mammography, ultrasound, and/or MRI, and
included: nine FA, one HA, and one FC. From these lesions,
histological results were available prior to this study for two
FA and one FC. These lesions were diagnosed in women
with BRCA mutation who undergo annual MRI follow-up.Table 5
Generalized linear model (generalized estimating equations, GEE) with binary ou
patterns as predictor variables.
Coefficient B Standard error
Curve type
Persistent 3.603 1.149
Plateau 1.892 0.760
Washout e e
ADC (103 mm2/s) e e
1.51e2.53 e e
1.18e1.50 0.993 0.816
1.17 3.593 1.047
95% CI, 95% confidence interval.Fig 2 shows a benign lesion in a 34-year-old womanwith
a suspected breast mass with 13 mm located in the outer
quadrant of the right breast.
Association between ADC and DCE-MRI kinetic
parameters
The association between ADC values and DCE kinetic pa-
rameters were evaluated for all the lesions (Table 3). A sig-
nificant associationwas foundbetweenADCvalues andpeak
initial enhancement (p<0.001). The same was observed be-
tween ADC and curve type. Lesions with higher ADC values
displayed persistent enhancementmore often thanwashout
or plateau enhancement curve patterns (p¼0.004).
Fig 3 presents ADC distribution by curve type and a
comparison of ADC values between curve types. Regarding
the pairs of curve types (Bonferroni test) only the pair
washout/persistent was significantly different in ADC
values (p¼0.003).
Univariate comparison between ADC and kinetic
parameters by lesion type
The results for the comparison between malignant and
benign lesions using ADC and DCE kinetics are presented in
Table 4. When comparing mean ADC values by lesion type,
benign lesions displayed higher ADCs than malignant ones
(1.740.38103 mm2/s versus 1.110.49103 mm2/s;
p<0.001).
The early phase seems to be a good predictor of malig-
nancy (p<0.001). In the present study, none of the malig-
nant lesions presented slow gadolinium uptake. Most of the
benign lesions (80.5%) showed medium uptake, 14.6%
showed rapid, and 4.9% slow uptake. A strong overlap was
observed between benign and malignant lesions, especially
between medium and rapid uptake.
When the analysis was performed by curve type, ma-
lignant lesions showed a higher number of lesions with
washout compared to benign ones (p<0.001). Seventeen
malignant lesions presented a plateau curve (60.7%); 11
(39.3%) had shown washout and none presented a persis-
tent curve.
More than 50% of the benign lesions showed a persistent
curve, while the other 43.9% showed a plateau pattern. The
remaining 4.9% of the benign lesions, corresponding to two
lesions presented washout curves.tcome malignancy using apparent diffusion coefficient (ADC) and curve type
Wald p-Value 95% CI
9.826 0.002 5.855; 1.350
6.201 0.013 3.381; 0.403
e e e
12.801 0.002 e
e e e
1.481 0.224 0.606; 2.592
11.785 0.001 1.542; 5.645
Table 6
Probability of malignancy for apparent diffusion coefficient (ADC) quartiles and the curve type.
ADC Quartile ADC range
(103 mm2/s)
Curve type
Persistent Plateau Washout
No. Probability of malignancy (%) No. Probability of malignancy (%) No. Probability of malignancy (%)
1 Q e 25% 1.17 2 54.6 7 86.9 8 97.8
2 Q e 50% 1.18e1.50 6 8.2 9 33.1 2 76.6
3 Q e 75% 1.51 13 3.2 19 15.5 3 54.8Multivariate analysis for lesion discrimination
A GEE analysis was performed considering: the ADC
values (classified based on quartile measurements to guar-
antee that each category included at least 25% of the le-
sions), the early phase, and curve type as predictors of
malignancy. According to the criterion of the lowest QICC
(the corrected quasi-likelihood under independence model
criterion), the model that best predicted lesion malignancy
included both ADC value and curve type (QICC¼56.931).
When the early phase was added to the model, the QICC
was worse (QICC¼58.165), and the effect of this parameter
was not found to be significant (p¼0.311). When only the
ADC values were used to predict malignancy, the QICC was
even higher (61.068), indicating that complementary in-
formation is indeed provided by the curve type parameter.
Table 5 presents the final results of the best model. Based on
the results of the GEE model with outcome malignancy and
independence working correlation, ADC and curve type
were independent predictors of malignancy (p¼0.003 and
p¼0.004, respectively). The predicted probabilities of ma-
lignancy based on the multivariable GEE model are sum-
marized in Table 6.
The predicted probabilities of malignancy for the first
ADC quartile corresponding to 25th percentile
(1.17103 mm2/s) were 54.6% for persistent, 86.9% for
plateau, and 97.8% for washout curve, respectively. For the
second ADC quartile (1.18e1.50103 mm2/s) the proba-
bilities of malignancy for persistent, plateau, and washout
curve types were 8.2%, 33.1%, and 76.6%, respectively. For
the third ADC quartile, corresponding to 75th percentile
(1.51103 mm2/s), the predicted probabilities of malig-
nancy were only 3.2% for persistent, 15.5% for plateau, but
more than 54.8% for a washout curve.
From the 69 lesions, 18.8% had a predicted probability of
malignancy <5% (with one malignant among 28 lesions)
and 50.7% had a predicted probability of malignancy >33%
(with 24/35 lesions, corresponding to a malignancy rate of
68.6%). Fig 4 illustrates an atypical cancer case corre-
sponding to an invasive lobular carcinoma classified as
grade II with strong initial enhancement followed by a
plateau curve type.Discussion
Breast cancer is one of the main public health problems
worldwide.37 As an adjunct tool to mammography and ul-
trasound, breast MRI is increasingly used, mostly due to itshigh sensitivity to detect and characterise early invasive
breast cancer.38
Previous studies on DCE-MRI8,15 reported kinetic pa-
rameters as having high diagnostic value and the washout
curve as a strong discriminator for lesion malignancy.27 DCE
images provide information about the rate of tissue
enhancement followed by the rate of contrast washout,
reflecting tissue vascularity, vessel permeability, and diffu-
sion in the extra-vascular space.12,39 Based on differences in
temporal enhancement, it is possible to distinguish benign
frommalignant lesions. Also, previous studies reported that
DWI is useful in the differentiation between benign and
malignant breast lesions.23,24 DWI provides functional in-
formation at the cellular level.40 Pathological processes
result in increased cellularity and structural changes, lead-
ing to a more compact tissue with reduced extracellular
space and water mobility.23 The ADC measures that re-
striction, serving as an indirect index of tissue complexity.
Recent studies reported that a protocol with both DCE and
DWI improves diagnostic performance and accuracy.27e30
Therefore, the physiological (kinetic parameters) and func-
tional (ADC) information derived from both techniques can
be used to predict malignancy.
In the present study, the mean ADC values of malignant
lesionswere significantly lower thanbenignones (meanADC
values for malignant lesions were 1.110.49103 mm2/s
and for benign 1.740.38103 mm2/s), in the range of the
mean ADCs published by other groups.41,42
The association found between ADC and kinetic param-
eters indicates that both can contribute to lesion charac-
terization. In the present study, the higher mean ADC values
were associatedwith persistent enhancement and the lower
ADCs with lesions with rapid enhancement and plateau/
washout patterns. A previous study reported that these ki-
netic characteristics are frequently associated with lesions
suspicious of malignancy.27 Also, Partridge et al.43 studied
the relationship between DCE kinetic features and ADCs,
and they found a significant association only between the
ADC and the curve type. In the present study, a significant
association was found between the ADC and both kinetic
parameters. Although there are differences in the analysis of
the early phase, as the authors of that study measured SI
variation along the early phase of the DCE,43 the most
probable explanation is the nature of the neoangiogenesis of
the lesions was different in the present study.
Comparison between benign and malignant lesions
showed that the ADC value, early phase, and curve type are
strong predictors for lesion discrimination; however, a
Figure 4 A 50-year-old womanwith a suspected mass lesionwith 11 mm located in the transition of the superior quadrants of the left breast. (a)
Sagittal DWI image at b¼1000 s/mm2 revealed an isohyperintense mass lesion (arrows), and (b) the corresponding hypointensity in the ADC
map (arrows). Image (c) is an early-phase subtraction of the DCE sequence. The lesion presents irregular borders and heterogeneous signal
intensity. (d) The kinetic curve shows strong contrast enhancement in the early phase, followed by a plateau curve. The histological result
showed an invasive lobular carcinoma with an ADC value of 1.36103 mm2/s. The asterisks on (a) and (b) illustrate a simple cyst with high
signal on both b¼1000 s/mm2 and ADC map because of the long T2 relaxation time of the fluid (T2 shine-through).strong overlap was observed in the early phase, with ma-
lignant lesions showing medium and benign lesions
depicting rapid uptake of gadolinium.
Although malignant lesions more often displayed a
washout pattern when compared to benign lesions, two
benign lesions presented a washout pattern and low ADC
values, namely one FA and one FC. The most probable
explanation is that these lesions, presenting high cellularity
due to increased proliferation, also show increased neo-
vascularisation activity.
A strong overlap in the plateau pattern and ADC values
was also found for benign and malignant lesions. Some
malignant lesions presented plateau curves and higher ADC,
namely two DCIS and two ILC lesions, and benign lesions
presenting a plateau pattern and lower ADC values (one FC
and one CSA). This overlap in kinetic imaging features and
ADCs values had already been reported by other groups44,45and is related to the wide spectrum of breast lesion het-
erogeneity, even within the same histological type.
Multivariate analysis revealed that the model that best
predicted lesion malignancy incorporates information
regarding both ADC and curve type. Lower ADC values and
plateau or washout curves were the best predictors of ma-
lignancy. A previous study developed by Yabuuchi et al.27
used correlation to evaluate the diagnostic accuracy of
several discriminators for benign versus malignant
enhancing mass lesions using the same pulse sequences as
the present work. The authors found some morphological
characteristics, plateau andwashout curves and ADC values,
to be the strongest discriminators between benign and
malignant lesions. In the present study, the predicted
probabilities of malignancy were higher when a washout
pattern is present and the ADC is 1.17103 mm2/s. Using
the ADC and curve type as predictors, the malignancy rate
was 68.6%, with 19 from the 28 malignant lesions correctly
classified. Based on the stratification of ADC and curve type,
malignancy prediction could be useful in the clinical setting
to reduce the number of unnecessary biopsies, thus
improving lesion management.
In the present work the focus was the physiological in-
formation retrieved from DCE-MRI. Although morpholog-
ical features (type, shape, margin, distribution, and internal
enhancement pattern) were not used to predict malignancy,
the inclusion of those features could further improve the
predictive probability of the model.
Although in the authors’ breast unit the reference stan-
dard for suspicious lesion management is to perform biopsy
before the MRI examination, for the present study patients
who had previously undergone biopsy were excluded to
minimize the presence of haematoma and/or oedema, as
these would have influenced the ADC estimates. If oedema
is present, an increased in the ADC is expected as the extra
fluid reduces the density of barriers hindering themotion of
water molecules. The presence of haematoma leads to a
reduction in T2* due to the iron in the lesion, reducing the
signal and thus making ADC estimates less reliable.
The present study had some limitations. Firstly, nine le-
sions were classified based only on the stability of imaging
features upon follow-up. Secondly, the number of benign
lesions was higher than the malignant ones, introducing
some bias in the predictive model of malignancy towards
benign lesions.
In conclusion, the information derived from DCE and
ADC reflects different information on lesion characteristics.
The combination of both examinations could be used in the
clinical practice to estimate the predictive value of lesion
malignancy. A future study with a larger sample could
enhance the predictive value of malignancy.
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